JMP Securities Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $142
Author: Benzinga Newsdesk | September 25, 2025 08:13am
JMP Securities analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Market Outperform and raises the price target from $135 to $142.